Elacestrant With/Without Triptorelin in Premenopausal Women With Luminal Breast Cancer
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2026-02-01
Target enrollment:
Participant gender:
Summary
PREMIERE parallel, non-comparative, two-arm, randomized 1:1, open-label, multicenter, exploratory window of opportunity study in premenopausal women with primary operable HR+/HER2-negative breast cancer with aiming at evaluating the biological effects of elacestrant with or without triptorelin.